Liz Highleyman

Prestigious prize goes to researchers who identified B cells and T cells and others who invented the HER2 targeted cancer therapy Herceptin.

Some groups, however, including Black and Latino men and homeless people, are not faring as well as others.

The newer tenofovir formulation can raise cholesterol and triglyceride levels, but these changes are reversible.

Half of adolescents remain unprotected against virus that causes anal, cervical and oral cancer.

Having both chlamydia and high-risk HPV16 dramatically increases the risk of anal precancer.

Cabotegravir plus rilpivirine maintenance therapy worked equally well when taken monthly or every two months.

The first-ever vaccine against the common sexually transmitted infection appears safe and active.

Pretomanid triple therapy cuts the length of treatment from 18 months to six months.

Evidence supports new PrEP option for gay men and trans women, but there’s no consensus for other groups.

The World Health Organization recommends this highly effective antiretroviral for all population groups, including young women.

Large European study finds that more than 1 in 10 people with HIV acquire HCV again.

Cure rates are high, but some young people already have advanced liver damage by the time they’re treated.

Descovy may offer protection against HIV faster and for longer than Truvada, but its higher cost may outweigh the apparent benefits.

French study finds taking meds for four days with three days off is as effective as daily therapy—and costs 43% less.

Early study shows implants delivers protective concentrations of a new antiretroviral for more than 12 months.